

## Keyword Index

2SLGBTQ+	A152, B168
2SLGBTQIA	B118
A	
academic-community partnership	B094
access	B100
access to cancer care	A101
access to care	B127, C125, C1
accessibility in clinical trial studies	B003
acculturation	B154
acute lymphoblastic leukemia	A032, C015, C076
acute myeloid leukemia	C068
adenocarcinoma of colon	C116
adherence	B067
adiposity	A059
admixture	A085
adolescent	A065
adolescent health	A066
adrenal crisis	C068
advance care planning	C005
adverse childhood experiences	B015, C031
advocacy	B106, C038
affordability	B127
Affordable Care Act	PR007, C136
aflatoxin B1	C116
africa	A028
African American	A061, A065, A098, B126, B136, C109, C114, C117
African American breast cancer survivors	B134
African American prostate cancer survivors	A088
African American women	A111
African Americans	IA053, B079
African ancestry	A036, C089, C093, C117, C154
African immigrant health	B144
age at diagnosis	A157
age at menarch	A029
aggressive malignancy	C161
aging	A102
air pollution	A048, A050

Akoya Biosciences, Inc.	C117
alcohol use	A094
All of Us Research Program	B014
allostatic load	PR011, B154, C079
allostatic load/stress	B157
alpha-enolase	C029
American Indian	B091
American Indian adults	PR005, B016
American Indian/Alaska Native	A158
American Indians	A132
ancestry	A007, A079, B008, B012, C051, C169
androgen deprivation therapy	A075
androgen receptor (AR)	C122
angiogenesis	A035
animated videos	A150
annonacin	C026
anthracycline-taxane chemotherapy	B006
Appalachia	C166
Arab Americans	A109
area deprivation	A058
aryl hydrocarbon receptor	C049
aryl hydrocarbon receptor repressor (AHRR)	C167
Asian American	A066, A103, C040
Asian American and Native Hawaiian and other Pacific Islander women	C046
Asian American and Native Hawaiian and Pacific Islander populations	A161
Asian American and Native Hawaiian/Pacific Islander (AANHPI)	A072
Asian Americans	B176, B177, B178
assessment	C140
attitudes	A090, A116
audit	PR016, B020
autoantibody	C159
awareness	A116
aya	A106
azd-1775	C025
B	
barriers	A139, B122, C135
behavioral research	B172

Behavioral Risk Factor Surveillance System (BRFSS)	A119
bioinformatics	B008, B009
biomarker	A031
biopsy	C180
birth cohort	A024
Black	A134
Black Americans	A133
Black Belt	A081
Black men	B028, B041, B171
Black patients	A087
Black PCS survivors	C042
Black women	A047, B039, B063, B101, B156, C148
Black women's health	B159
Black/African American	C162, C171
brain neoplasms	B140
breast and colorectal cancer	B050
breast cancer	PR008, A004, A012, A021, A027, A036, A050, A053, A058, A060, A089, A097, A102, A128, A135, B004, B033, B039, B063, B066, B079, B096, B101, B111, B149, B168, C005, C008, C013, C023, C024, C030, C039, C061, C088, C090, C119, C137, C143, C145, C146, C149, C152, C181
breast cancer disparities	IA053, A103, C063, C105
breast cancer prevention	A111, B070, B071
breast cancer related cytokines	B150
breast cancer risk	C150
breast cancer screening	A096, A119, A130, B048
breast cancer screening adherence	A151
breast cancer screening/mammography	A154
breast cancer subtypes	C101, C153
breast cancer survivor	C040
breast cancer survivors	C036, C046, C062
breast cancer type 1 (BRCA1)	A020
breast local and systemic immune microenvironment	PR006, C090
breast tumor biology	PR006, C090
breast tumor genomic assays	C022
breast tumor immune microenvironment	C089
breastfeeding	A014, B070

building capacity	C007
building trust	B094
<b>C</b>	
California cancer Registry	A025
cancer	PR012, A011, A081, A110, A167, B001, B002, B057, B061, B153, B172, C009, C095, C139
cancer advocacy	B112
cancer beliefs	A030
cancer biology	C096
cancer burden	A046
cancer care delivery	C131
cancer care disparities	B104
cancer care equity	C130
cancer clinical trials	B025
cancer communication	B034
cancer death risk	B157
cancer disparities	A005, A165, B005, B076, B120, B136, C100, C106, C173
cancer driver mutations	C171
cancer education	B093, B103
cancer epidemiology	A016
cancer genetics	C084
cancer genetics clinical and research referrals	B055
cancer genetics training	B115
cancer genomic databases	A080
cancer genomics	C106
cancer health disparities	B121, C120, C179
cancer health disparities/populations science	B119
cancer health equity	B058, B080
cancer incidence	PR015, A078
cancer inequities	A077
cancer metabolism	C016
cancer mortality	A040, A071
cancer navigation	A160
cancer outcomes	A009
cancer patients	A100, C041, C124
cancer prevention	A016, B026, B053, B082, B147
cancer prevention and control	B099
cancer prevention and screening	C179

cancer prevention guidelines	A016
cancer research	B107
cancer research training	B095
cancer risk	A057
cancer risk behaviors	B015
cancer risk management	B090
cancer risks	B005
cancer screening	PR012, A120, A125, A126, A155, B060, B153
cancer screening education	B045
cancer survival	A041, A074
cancer survivors	A052, B052, C031, C041, C043, C131
cancer survivorship	B165
cancer treatment	C033, C057
cancer well-being	B179
cancer-related financial hardship	C073
cancerresearch	B108
cannabis use	B014, B015
capacity building	C132
capacity-building	B099
cardiometabolic biomarkers	B014
cardiotoxicity	C032
cardiovascular disease	C041, C044, C045
cardiovascular health	C041
caregiver	B081
caregiver burden	B081
caribbean	B113, C177
Caribbean global health	C175, C176, C178
castration resistant prostate cancer	C052
catchment area disparities	C181
cell lines	C168
centrosome kinases	C151
cervical cancer	A112, A121, A146, A156, A162, B089, B113, C111
cervical cancer disparities	B064
cervical cancer screening	A113, A117, A118, A142, A144, B007, C174, C175, C177
cervical cancer screening and follow-up	C132
cessation	A091, B017
chemotherapy	A012

childhood cancer survivors	B139
chimeric antigen receptor (CAR)-T therapy	B105
cholesterol pathway	C103
chromatin acetylation	C115
chromatin immunoprecipitation sequencing (ChIP-seq)	B011
chronic health conditions	B139
chronic hepatitis B	A063
cisplatin	C051
CITIES	A096
clinical research	B174
clinical study design	B086
clinical trial	B033
clinical trial diversity	B123
clinical trials	B039, B096, B109, B114, B136, B142, B160, B174, C048, C070, C164
clinical trials and genomic research	B119
clinical trials awareness	A107
clonal hematopoiesis	A017
cluster analysis	A057
cognitive function	C047
cohort study	C128
collaboration	C011
collagen disorder architecture (CODA)	C117
collagen proteome	C003
colonoscopy	B110
colorectal	A011, A167, B152
colorectal cancer	A009, A048, A049, A056, A076, A122, A129, A153, A157, B065, B109, B110, B137, C059, C103, C104, C106, C110, C154, C155, C156
colorectal cancer (CRC)	B166
colorectal cancer campaign	B024
colorectal cancer disparities	C157
colorectal cancer research	A080
colorectal cancer screening	A127, A133, A137, A140, A141, A150, B085, B151, C129
colorectal health	B091
colorectal neoplasia	C094
cometchip assay	A034
commercial tobacco	PR005, B016

common cancers	C083
common variable immunodeficiency (cvid)	C066
communication	C013
communication resources	B027
community	A110, B035
community advisory board	B076, B098
community advisory boards	B093
community education	B056
community engaged research	B084
community engagement	A133, B028, B055, B076, B080, B082, B091, B170
community engagement studio	B086
community health	A122, B057
community health centers	C043
community health worker	A124, A156
community health workers	B055, B082
community health workers (CHWs)/promotoras/navigators	A160
community living labs	B073
community outreach and engagement	B060, B088
community recruitment	B118
community scientist	B107
community voices	B098
community-academic partnerships	B130
community-based educational intervention	B054
community-based health collaboratives	A159
community-based intervention	B048
community-based organizations	B151
community-based participatory research	B078, B083, B085, B094
community-engaged	B090, C152
community-engaged research	B004
comorbidities	B150
complexities in outcomes	A165
concept mapping	B089
continuing education	B115
Continuing medical education (CME)	B104
county-level income and rurality	C045
COVID-19	A140, B030, C129
cultural education	A129
cultural sensitive	B024
cultural tailoring	B043

culturally	A167
culturally adapted nutrition education	B159
culturally tailored	B103
culturally tailored interventions	A005
culturally targeted smoking cessation intervention	B019
culture	B045
culture of belonging	B125
curriculum	B162
cyclin-dependent kinase inhibitor 2A (CDKN2A)	C123
cysteine-rich angiogenic inducer 61 (CYR61)	C098
cytokines	C118
cytotoxic assays	C054
<b>D</b>	
darolutamide	C162
decentralizing cancer research	B088
deep vein thrombosis	A099
definitive treatment receipt	C074
delay to breast cancer treatment	C063
dermatofibrosarcoma protuberans	B138
developmental evaluation	C011
differential expression genes	C094
differentially expressed genes (DEGs)	C101
digital health	B037
digital storytelling	A115
disability	C137
disaggregation	A072
disaggregated Asian American and Pacific Islander	A069
discrimination	A068
disease burden	A028, C001
disparities	PR013, A022, A032, A035, A037, A097, A104, A119, A135, A137, A145, B018, B047, B067, B148, C002, C061, C117, C126, C164
disparities and ovarian cancer	A006
disparities in racial/ethnic minorities	C064
disparities research	A008
disparity	A029, C065
disparity research	C054
displaced community	C133
distress	B141
diverse datasets	B170

diverse populations	A142
diverse research participation	B058
diversity	A071, C019, C140
diversity in trials	B025
diversity recruitment	A115
diversity, equity, and inclusion	B175
DNA methylation	A060, C087, C114
DNA repair	A034
drug delivery	C027
drug response	C049
drug screening	C172
ductal carcinoma in situ	C045
dyadic analyses	B072

## E

early phase clinical trial	B122, B123
early-onset	A049, B166
early-onset colorectal cancer (EOCRC)	C157
East African	B103
ecologic analysis	C009
economic segregation	A040
education	B063
education and training	B175
electronic cigarette	A013
electronic health records	A161
electronic health records (EHR)	B037
electronic health records (EHR) data	A130
electronic medical record	A145
emergency room visits	C059
empowerment	B066
endocrine disrupting chemicals	C113
end-of-life care	C134
endogenous retroviruses	C092
endometrial cancer	A018, B161, C057, C163, C165
engagement	B035
engagement methods	A127
enolase	C159
Enolase 1 (ENO1)	C029
environmental justice	A056, C078
enzalutamide	C052
ephrin type-A receptor 4 (EPHA4)	C145

epidemiology	A102
epidermal growth factor receptor (EGFR) mutated non-small-cell lung cancer (NSCLC)	A087
epigenetic	A031
epigenetics	C115
Epstein-Barr virus (EBV)	A026
equitable healthcare	B104
equitable relationships	B164
equity	A028
ER+ breast cancer	A042
esophageal cancer	A083
estrogen receptor	A036, B011
ethnic disparities	A027
ethnicity	PR009, A073, A085, B051, C075
ethnicity and survival rates	C157
eukaryotic translation initiation factor 4E binding protein 1 (4EBP1)	C024
evidence-based interventions	C132
excess death	C139
exposure science	C078
extremely dense breasts	A136
<b>F</b>	
facilitators	A139
facilitators and barriers	A149
familial risk	B034
familismo	B081
family history	A128, B090
fecal immunochemical test (FIT)	B110
Filipino	A129
Filipino community	B024
financial literacy	B054
financial toxicity	A100, B054, B142, C048
fitness	B068
focus groups	B163
food environment	A040
food insecurity	PR002, B129, B143, B145, B173
food prescription	B129
food security	B048
forkhead box A1 (FOXA1)	B011

forkhead box O3a (FOXO3a)	C030
Formalin-Fixed Paraffin-Embedded (FFPE) samples	C094
fruits and vegetables	B143
functional well-being	C060
<b>G</b>	
gastric cancer	A001, C158
gemcitabine	C025
GEMINI gene	C099
gender affirming	B042
gender identity	A002
gene expression	PR008, C087, C146
gene mutations	C086
generational status	PR014, A067
genetic	B100
genetic ancestry	C083, C143
genetic counseling	B102, C125
genetic mutation	B111
genetic navigation	B065
genetic predisposition	C163
genetic screening services	A147
genetic testing	A138, B101, B102, C086, C152
genome instability	C075, C076
genome organization	C015
genome-wide association study (GWAS)	A021
genomic education	B093
genomic medicine	B023
genomic screens	C091
genomic testing	C070
genomics	A079, A084, C023, C093, C099, C102
genomics training	B167
genotyping	C050
geopolitics	C004
Georgia	A157
geriatric oncology	C071
germline	C123
germline testing	A020
germline variant of unknown significance (VUS)	C010
glioblastoma	C080
global disparities	C001

guideline adherence	B007
guideline-concordant care	PR007, C136
gynecologic cancers	C002
H	
H. pylori knowledge	A064
head and neck cancer	B013
head and neck squamous cell carcinoma (HNSCC)	A094
survival	
health and faith	B050
health communication	B026, B083
health disparities	A014, A047, A076, A093, B043, B072, B112, B156, B169, C020, C056, C113, C122, C139, C154
health disparity	A166, C077
health education	B109, B111
health equity	A015, A110, B002, B018, B088, B097, B098, B125, B147, B170
health expenditure trajectory	A001
health insurance	A082
health literacy	B049
health navigators	B167
health promotion	B075
health status disparities	B140
healthcare	C135
healthcare access	A125, B128
healthcare costs	C134
healthcare disparities	PR007, C136
healthcare utilization	C124
hedgehog	C100
hematopoietic cell transplantation	C044
hematoxylin and eosin images	C022
hepatitis B	B074
hepatocellular cancer	C027
hepatocellular carcinoma	PR002, A024, B145
hepatocellular carcinoma (HCC)	A045
hereditary syndromes	C158
hints	A123
Hispanic	A120, B027, C095
Hispanic cancer patients	A101
Hispanic disparities	C104
Hispanic population	C103

Hispanic prostate cancer	C100
Hispanic/Latin American women	C024
Hispanic/Latino	A009, B077, B102, B106, B155, C123
Hispanic/Latino ancestry	C153
Hispanic/Latino breast cancer	C085
Hispanic/Latino cancer patients	A008
Hispanic/Latino health	PR015, A078
Hispanic/Latino health disparities	C076
Hispanic/Latino smokers	B022
Hispanic/Latino women	C149
Hispanic/Latinx	B154
Hispanics	A105, A163, B031, B038, C110
Hodgkin lymphoma	A026
Hodgkin lymphoma treatment	C072
homelessness	B064
hormonal carcinogenesis	C113
hormone receptors	C144
hospice services	C134
hospitalizations	B013
houston	C082
HPV infections	A002, A112, B078, C017
HPV prevention	A162
HPV self-collection	B089
HPV self-sampling	A121
HPV vaccination	A143, A164, B027, C006
HPV vaccine	A065, A066, A146, A163, B069
HPV-associated cancers	A109
HPV-related cancers	A163, B069
human epidermal growth factor receptor 2 (HER2)	B006
negative breast cancer	
human immunodeficiency virus (HIV)	A013
Human papillomavirus (HPV)	PR004, A002, A112, B078, A109, A123, A144, B047, C107, C176
hurricane floods	C055
hyperinsulinemia	A018
hyperthermic intraoperative peritoneal perfusion with chemotherapy (HIPEC)	C069
hypogammaglobulinemia	C066
hypoxia	C105

I	
immigrant	C039
immigrant health	B144
immigrants	B002
immune	A023, A042
immune checkpoint inhibitors (icis)	C170
immune related adverse events	C170
immune response	C118
immune thrombocytopenia	C067
immune-related adverse events	C067
immuno-oncology	C164
immunotherapy	C021, C035
implementation improvements	C073
implementation strategies	A154
inclusion of people with sensory disabilities	B003
inclusive excellence	B125
income quintile	B006
Indigenous health	A148
indoor radon	C077
inequality	B061
inflammation	A018
inflammatory breast cancer	C037
inflammatory markers	B087
insulin resistance	C115
interferon	C112
interleukin-6 (IL-6)	B087
interrupted time-series analysis	A010
intervention	A095, B038
interventions	B080
intra-abdominal neoplasm	C069
iron deficiency anemia	A099
K	
Kenyan global health	C174
kick vaping	B017
kidney cancer	A059
kisspeptins	C111
knowledge	A090, A116
Korean community	B050
KRAS	B009, C028

L	
lactation	B071
language	B173
language barriers	B077
large scale	B170
large scale approaches to cancer gene discovery	C102
latent class analysis	C047
late-stage breast cancer	B131
Latina cancer survivors	B143
Latina health	A147
Latina participation decisions	B033
Latino	B017, B032, C095
Latino advocates	B169
Latino cancer disparities	B032
Latino cancer patients	B158
Latino health equity	B032
Latino men	PR014, A067
Latino young smokers	B021
Latinx	A108
learner verification and revision	A150
learning health system	B073
leukemia	PR011, A079, C079
LGBT	A126
LGBTQ	PR016, B020, B092
LGBTQ+	A113
LGBTQ+ community	B042, C006, C007
Life's Essential 8	C041
lifestyle behaviors	B060
lifestyle intervention	B062
limited English proficient	C137
linguistic analysis	B049
liver cancer	B074, C112
liver cancer mortality	A025, A054
liver cancer surveillance	A161
loneliness	B134
loss of heterozygosity (LOH)	C099
louisiana	A126
low cost microscopy	C016
low-dose computed tomography (LDCT)	B046
low-income	B173
lung	C168

lung adenocarcinoma	B009, C167, C171
lung adenocarcinoma (LUAD)	C168, C169
lung cancer	PR001, A003, A019, A098, A105, A114, A125, B037, B116
lung cancer education	B040
lung cancer incidence	A010, C173
lung cancer screening	PR005, A132, A139, A145, A148, A149, B016, B040, B044
lung cancer survival	C077
lymph node	C142
lymphocyte count	C019

## M

machine learning	A008, B012, B019, C008, C022
magnetic resonance imaging	C180
Malayali tribes	A092
malignant peritoneal mesothelioma (MPM)	C069
mammogram screening	A152
mammography	A131
mammography allocation	C181
mammography screening	A015
medical learners	B035
medical mistrust	B029
medical student	B040
medication adherence	B117, B149, C053
men living with HIV (MLWH)	C178
mental health	B155, C055
mentoring	B124
metabolic plasticity	C091
metabolic reprogramming strateg	C109
metabolic syndrome	A063
metabolism	C084
metabolomics	A033
metal-organic frameworks	C027
metastasis	C050
metastatic	A039
metastatic breast cancer	C128
metastatic castration resistant prostate cancer	C160
metastatic status	C037
methylation	C108
mHealth	B117

microbiome	PR009, A073
microenvironment	C003
minority health	A103
minority health disparities	A162
minority populations	C086
minority research participation/navigation	B119
missing cancer care	C133
mistrust	B128
mitochondria	C020, C169
mitotic kinases	C141, C151
mobile technology	B021
modeling	PR001, A003
molecular docking	B010
molecular dynamics simulation	B010
molecular mechanics with generalised Born and surface area solvation (MM/GBSA)	B010
molecular subtypes	A032
moonshot	A005
mortality	A069, A104, C019, C127, C128
mosaic chromosomal alterations	A017
mRNA vaccine	B010
multi-cultural	B047
multiethnic	A026
multiethnic cohort	A048, A086, C040
multilevel	A137
multilevel analysis	C005
multilevel intervention	B085
multilevel interventions	B058
multilevel social determinants/drivers of health	C004
multimodal imaging	C003
multimorbidity	B148
multiomic sequencing	C117
multiple myeloma	A047, B141
multiplex immunohistochemistry	C120
muscle soreness	B030
mutational signatures	C010

## N

nanosting	C117
National Death Index (NDI)	A045
National Health and Nutrition Examination Survey (NHANES)	C047

National Health Interview Survey	A113
Native American	A084, B044
Native American health	A148
Native Americans	B036
Native Hawaiian/Pacific Islanders	PR012, B153
nativity status	A096
negative predictive value	C014
neighborhood	A039, B152
neighborhood analysis	A147
neighborhood characteristics	B135
neighborhood deprivation	A037, A055
neighborhood environment	A052
neoadjuvant chemotherapy	C023
neoantigen	B010
nested case control study	A001
neurite outgrowth	C081
neuroendocrine tumors	A070
neuro-oncology	C056
neurotoxicity	C051
New York	A083
non-Hispanic Black	A033
non-Hispanic White	A033
non-small cell lung cancer (NSCLC)	C021
Notch and Wnt pathway	C100
nutrition	B116
O	
obesity	A059, A060, A061, C148
obesity related cancer risk	B130
obesity-related cancer risk	B053
obesogenic environment	C009
obstructive nephropathy	C161
older Hispanic women	A117, A118
older patients with cancer	B029
oncology	B155
oncosexology	C053
Oncotype Dx	A055
online communication	A164
opioid use disorder	B013
organoid	C172
oropharyngeal cancer	C004

oropharyngeal squamous carcinoma	PR004, C107
osimertinib	A087
outcomes	PR013, A022
outreach strategies	B036
ovarian cancer	B177, C075, C166
ovarian cancer prevention	B070
ovarian cancer risk factors	A006
ovarian cancer survival	B178
ovarian cancer treatment	B176
ovarian clear cell carcinoma	C084
overall survival	C144
P	
Pacific Islander	B045
pain	B030
palliative care	B132
pam50 subtype	C022
pancreatic cancer	C025
Pap test	A146
paraesophageal hernia (PEH) with cancer	B132
participant engagement	A084
partnership building	B097
pathogenic/likely pathogenic variants	A020
pathomics	C022
patient advocacy	B001
patient advocate	B004
patient education	B105
patient education material	B025
patient experience	B023, B160
patient information quality	B105
patient navigation	A153, C130
patient navigation for lung cancer screening (LCS)	A158
patient navigator	B049
patient provider communication	C074
patient reported outcomes	B140
patient-centered communication	B029
patient-provider communication	A068
PD-L1 expression	C149
pediatric	B135
pediatric cancer	B067, B133
pediatric cancer survival	A051

pediatric leukemia	C087
people with HIV	A114
peptidase	C108
peptide–protein interaction	C090
persistent opioid use	A097
persistent poverty	A046, A149, B130
personal care products	A077
personalized navigation	C073
Persons Living with HIV (PLWH)	C176
Philadelphia Chromosome	C015
physical activity	A108, B057, B062, B072, B079
physical and mental health status	A052
physical function	B068
plasmacytoma variant translocation 1 (PVT1)	C097
platelets	C080
policy	B168
polygenic risk score	A021
polyisoprenylated cysteinyl amide inhibitors (PCaIs)	C028
polyphenols	A019
population based research	C127
population genomics	B012
poverty	A042, B127
precancerous cervical lesions disparities	C017
precision medicine	C172
precision oncology	B023
predicting ovarian cancer	A006
preferred language	B179
pregnancy-related medical conditions	A014
Pride events	C006
primary adrenal insufficiency	C068
prognosis	A004
prognostic variables	C101
programmed cell death protein 1	C067
prostate	A134, C098, C108

prostate cancer	PR013, A022, A031, A034, A035, A041, A075, A086, B028, B034, B041, B062, B068, B073, B083, B106, B146, B171, C001, C014, C018, C020, C049, C054, C060, C074, C097, C098, C114, C117, C122, C159, C162
prostate cancer health disparities	C092
prostate cancer incidence	PR014, A067
prostate cancer risk clinical trials	A115
prostate cancer screening	C178
prostate cancer survivors	B144
prostate cancer-specific mortality	A086
prostate MRI	C014
prostate-specific antigen (PSA)	B041
prostate-specific antigen (PSA) testing	B084
prostatic neoplasms	C180
protein phosphatase 2C delta (Wip1)	C030
proteomics	A039, C052
psychological distress	C059
psychosocial interventions	IA053
psychosocial support	B165
psychosocial, interpersonal, and structural stressors	PR006, C090
public health intervention	A159, B075
Puerto Rico	A010, A100, A101, C082
pulmonary thromboembolism	A099
<b>Q</b>	
qualitative	B092
qualitative evaluation	B095
qualitative interviews	A130, C042
qualitative methods	B096
quality	A131
quality of life	A068, B059, B066, C042, C055
quitsites	PR016, B020
<b>R</b>	
race	PR009, A055, A056, A071, A073, A085, B051, C065
race and ethnicity	PR008, C144, C146, C150
racial and ethnic disparities	A025, C037, C062, C155

racial and ethnic disparity	A082
racial and ethnic minorities	A080
racial concordance	A064
racial differences	C160
racial disparities	PR001, PR004, A003, A038, A058, A081, B131, C013, C060, C097, C107
racial disparity	A030, C119, C147
racial disparity in breast cancer	C121
racial segregation	A051, C008
racial/ethnic disparities	B007, B161, B176, B177, B178, C035, C036
racial-ethnic disparities	A074
racism in healthcare	A155
radium-223	C160
randomized	C032
randomized clinical trial	B126
rapid review	B160
rat sarcoma (RAS)	C028
recruitment	B116, B126
rectal cancer	B077
recurrence	C050
recurrence score	C022
redlining	A053, B139, C078
reflectivepractice	B108
relevance index	C124
renal amyloidosis	C066
renal cell carcinoma	C091
representation	B123
reproductive cancer disparities	B159
research	A124
research advocacy	B107
research participation decision making	B118
research prioritization	B084
resilience	C031
retention	B124
risk factors	A027
risk prediction	A143
risk stratification biomarkers	C018
rural	A091, A095, B120
rural areas	A154

rural community	B097
rural disparity	C138
rural health	C166
rural surgery	C138
rurality	A049, A151, A164, C065, C138
rural-urban	B166
<b>S</b>	
S100 family signaling pathway	C110
safety net	B129, B148
scoping review	C033
screening	A122, A128, A135, A153, B046, B137
screening disparities	A121
second cancers	C046
second primary cancer risk	C062
secondary cancer	C061
self-help intervention	B019
self-sampling	A142, A156, B064
sequencing	B008
seroprevalence	A112
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	A141
sex	C156
sex differences	C170
sexual and gender minorities	A158
sexual and gender minority (SGM)	B005
sexual and gender minority health	B165
sexual minorities/LGB health	B157
Sexual Orientation and Gender Identity (SOGI)	B092
sexuality	B028
sign language	B003
signal transduction	C111
signaling pathways	C153
single nucleotide polymorphism (SNP)	C167
single-cell RNA sequencing (scRNA-Seq) & single-cell sequencing assay for transposase-accessible chromatin (scATAC seq)	C117
single-nucleus multiomics	C089
skin cancer	A023, B031, B038
skin cancer prevention	B056
small non-coding RNAs (sncRNAs)	C018

smoking	A095
smoking and lung cancer risk	C173
smoking cessation	B019, B021, B044
smoking cessation intervention	B022
smoking prevention	A093
Snail	C081
social and clinical factors	B134
social deprivation	A017
social determinants	A089
social determinants of health	PR011, A038, A054, A127, B051, B137, B147, B150, B151, C044, C056, C079, C163
social determinants of health and latinas	B117
social drivers of health	B149
social factors	B031
social media	B026
social networks	A111, B133
social risk	A054
social risks	C131
socio-determinants of health	B001
socioeconomic	B146
socioeconomic factors	A151
socioeconomic influences	B133
socioeconomic status	B138, B152, C155
socioeconomic status (SES) characteristics	B131
socioeconomic status (SES) disparities	C127
solid tumor	B135
somatic	C010
somatic alteration differences	C083
somatic profiling	C085
somatic-germline interactions	A007
sources of stress	B158
sources of support	B158
South Asian Americans	A074
Southern Nigeria	C116
Spanish language	B059
Spanish-speaking smokers	B019
spatial immune profile	C142
spatial profiling	C117
spatial transcriptomics	C165
spatial transcriptomics	C105

squamous cell carcinoma (SCC)	A019
stage at diagnosis	A082, A114, A132
steatotic liver disease	A063
stigma	B113
stomach cancer	A064
stool tests	A140
stress	A088, B156
stress reactivity	A089
stress response	C121
stress-survival pathways	C104
structural cisheteropatriarchy	A152
structural competency	A166
structural racism	A041
student education	C012
sub-Saharan Africa	B172, C022, C033
subtype	C039
superfund sites	A057
supplement use	B052
supplemental breast MRI	A136
supportive care	B179
Surface plasmon resonance (SPR)	C090
surgical delays	C063
survival	A004, A072, C065
survival rates	A046
survivor empowerment	C038
survivors of adolescent and young adult cancer	A120
survivorship	B043, C038
survivorship care	C043
survivorship care plan	C034
survivorship care plan (SCP)	C034
T	
Talin1	C081
targeted therapy	C021
technology-based weight loss	B053
telehealth	A123, A141, C125
telepathology	B061
terminal duct lobular unit (TDLU) involution	C143
testing	B100
text-based	C048
theranostics	C029

therapy resistance	C016
thoracic oncologic surgery	C064
timeliness	C135
tinnitus, hearing loss, and vertigo	C036
tobacco	A090, A091, B018
tobacco cessation	A159, B042
tobacco prevention	C007
tobacco smoking	A013
tobacco usage	A092
tobacco use	A093, A094
toll-like receptors	B010
town hall	B028
train the trainer	C179
train the trainer program	B065
trainee recruitment	B121
training	B169, C140
training and technical assistance	B099
training experience	B095
training program	B108, B112
transdisciplinary	A131, B163, B171, C011
transdisciplinary collaboration	B162, B164
transgender/gender diverse	B163
translations	B059
trans-population genetics	A007
travel distance & survival	A165
treat	C126
treatment	B138
treatment disparities	A075
Tribal health	B046
triple negative	C026
triple negative breast cancer	A037, C142, C148, C035, C141, C151
triple-negative breast cancer (TNBC)	C109
triple-negative breast cancer (TNBC)-subtyping	C147
trust	A124
tumor hypoxia	C121
tumor immune microenvironment	C156
tumor microenvironment	C080
tumor microenvironment	A061, C092, C118, C120, C165
tumor necrosis factor alpha (TNF- $\alpha$ )	B087
tumor suppressor	C119

Tyrer Cuzick and Gail models	C150
tyrosine kinase inhibitors	A106

## U

ultraviolet radiation	B056
underrepresented	B124, B146
underrepresented communities	A107
underrepresented populations	B120, B122
underserved populations	B115, B142
urbanicity	C065
urothelial carcinoma	C161
utilization	C129

## V

vaccine access	A002
vaginal microbiome	C017, C057, C082
variant	A011
vascular	C032
vertical	C126
video	A134
Vietnamese immigrants	A144
vincristine	C07
VirScan	A045
virtual reality (VR)	A108
vulnerability	B141

## W

webtool	A104
well-being	C034
women living with HIV	C174, C175, C177
women's health	A015, A166
workforce development	B174, B175
World Health Organization (WHO) Oral Health Assessment pro forma	A092

## Y

young adults	A105
young-onset breast cancer	A029